Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Epigenetic therapy in hematological cancers

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Orbital Lymphoma - An International Multicenter Retrospective Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Mother-child transmission of epigenetic information by tunable polymorphic imprinting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The immunomodulatory drug thalidomide, and its analogs, lenalidomide, and pomalidomide (IMiDs), have become essential components of the standard treatment for multiple myeloma (MM), and have led to significant improvement of survival in patients with this devastating disease. Cereblon (CRBN), the direct target of IMiDs, has been proposed as a predictive biomarker of response to IMiDs. Using standard immunohistochemistry in formalin-fixed paraffin embedded (FFPE) bone marrow samples of 23 patients treated with a lenalidomide-containing regimen, we found that the malignant plasma cells of all the patients stained positive for CRBN, IKZF1, and IKZF3, regardless of sensitivity to IMiDs. Moreover, we detected no mutations in CRBN, IKZF1, IKZF3, CUL4A, or IRF4, but found expanded TP53-mutated clones in two out of seven sequential samples. Thus, our data argue against the use of CRBN and its downstream targets as predictive biomarkers of IMiD response in MM and confirm clonal evolution patterns during lenalidomide resistance.

OriginalsprogEngelsk
TidsskriftLeukemia and Lymphoma
Sider (fra-til)180-188
Antal sider9
ISSN1042-8194
DOI
StatusUdgivet - 2 maj 2018

ID: 54781628